The regulatory and policy landscape surrounding mucinous cystic neoplasms (MCNs) represents a complex intersection of rare disease legislation, healthcare quality standards, and evolving clinical practice guidelines that collectively shape how these conditions are diagnosed, treated, and managed within modern healthcare systems. Understanding this regulatory...